Bicyclic heteroaryl derivatives

US10941147B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Bjoern Bartels · Schopfheim, DE
• Roland Jakob-Roetne · Inzlingen, DE
• Anja Limberg · Penzberg, DE
• Werner Neidhart · Hagenthal-le-Bas, FR
• Hasane Ratni · Habsheim, FR
• Michael Reutlinger · Glückstadt, DE
• Jérôme Charles Sarie · Basel, CH
• Greta Vastakaite · Basel, CH

Key dates

• Filing date: Oct 30, 2017
• Grant date: Mar 9, 2021
• Expiry date: Oct 30, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound of formula I, 1-1 or 1-2 wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, or lower alkoxy substituted by halogen; R1 may be different if n=2 or 3 n is 1, 2 or 3 Ar is a six membered heteroaryl group, selected from wherein R2 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen or lower alkoxy; R3 is hydrogen or halogen; or to a pharmaceutically active acid addition salt thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.